Homepage Top Section2

Based in Germany, Immatics is a clinical-stage biopharma company engaged in the discovery and development of T-cell redirecting cancer immunotherapies. The German firm is expected to develop T-Cell

The lead product candidate of Modis Therapeutics is MT1621, an investigational deoxynucleoside substrate enhancement therapy. Currently, MT1621 is in late-stage development for the treatment of Thymidine Kinase 2

The latest FDA approval is the third for Taltz with the first one coming in 2016 for the treatment of adults with moderate to severe plaque psoriasis. The

The company has reported positive headline results from the pivotal DREAMM-2 open-label and randomised study of two doses of belantamab mafodotin. Belantamab mafodotin is an immuno-conjugate, which included

Cabotegravir is an investigational integrase inhibitor (INI) developed by ViiV Healthcare, while Edurant (rilpivirine) has been developed by Janssen as a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the

The new facility is believed to support the company’s continuing investment in gene therapy research and development similar to its research and development sites in Chapel Hill and

As per the terms of the deal, Bayer will receive $5.3bn (£4.37bn) in cash and will be issued $2.3bn (£1.9bn) worth shares in the US-based Elanco Animal Health.

The investment secured by Sanfer is expected to help the company implement its continued expansion plans in Mexico and in other parts of Latin America. Additional terms of

The company has also received accelerated approval for Rozlytrek to treat adult and paediatric patients 12 years of age and older with solid tumours, which have a neurotrophic